FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Washington, D.C. 20049

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>DENKHAUS DONALD A</u>						2. Issuer Name and Ticker or Trading Symbol CATALYST PHARMACEUTICALS, INC. CPRX								5. Relationship of Reporting Person(s) to Issuer Check all applicable) X Director 10% Owner				
(Last) (First) (Middle) 355 ALHAMBRA CIRCLE SUITE 1250						3. Date of Earliest Transaction (Month/Day/Year) 12/02/2019								Office below	r (give title)		Other (s below)	pecify
(Street) CORAL GABLES (City)	RAL FL 33134 BLES - 33134					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tab	le I - Non	-Deriv	ative	e Se	curities	Ac	quired, D	isp	osed o	f, or Bei	neficial	ly Owne	d			
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date,			Code (Inst					Benefic	es ially Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code	<u> </u>	Amount	(A) or (D)	Price	Transac (Instr. 3	tion(s)			Instr. 4)
		-	Table II - I (uired, Dis , options					Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day/	ate, T	4. Transaction Code (Instr. 8)				6. Date Exer Expiration D (Month/Day/	ate		7. Title and Ame of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				c	Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares					
Options to purchase common stock	\$4.64	12/02/2019			A		33,500		(1)	12	2/02/2026	Common Stock	33,500	\$0	323,50	00	D	
Restricted Stock	(2)	12/02/2019			A		4,000		(1)		(3)	Common Stock	4,000	\$0	327,50	00	D	

Explanation of Responses:

- 1. Derivative securities vest in equal tranches, 1/3rd on December 2, 2020, 1/3rd on December 2, 2021 and 1/3rd on December 2, 2022.
- $2. \ Each \ restricted \ stock \ unit \ represents \ a \ contingent \ right \ to \ receive \ one \ share \ of \ the \ Registrant's \ common \ stock \ upon \ vesting.$
- 3. Shares of common stock will be delivered to the Reporting Person upon vesting.

/s/ Donald A. Denkhaus

12/04/2019

** Signature of Reporting Person

Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.